Resultado da gravidez em mulheres aloimunes e com síndrome de antifosfolípide
um relato de caso
Palavras-chave:
Síndrome do anticorpo antifosfolípide, Aborto habitual, Heparina, Aspirina, ImunoterapiaResumo
CONTEXTO: Mulheres com síndrome do anticorpo antifosfolípide e aloimunidade têm um mau prognóstico de gravidez. Existem muitas opções para o diagnóstico e o tratamento destas doenças, embora o tratamento mais adequado não esteja estabelecido. RELATO DE CASO: Apresentamos a evolução clínica e o tratamento de uma mulher com antecedentes de dois abortos e que vem sendo acompanhada, há 10 anos, em nosso serviço. Após o diagnóstico da síndrome do anticorpo antifosfolípide e de aloimunidade,, a paciente recebeu tratamento com heparina, aspirina e prednisona, além de imunizações com linfócitos. Nas duas gravidezes subseqüentes, teve dois bebês prematuros, que evoluíram com crescimento e desenvolvimento normais. A quinta gravidez não foi bem-sucedida, apesar de a paciente ter recebido um tratamento semelhante ao utilizado previamente embora após o início da gravidez, não planejada. Na discussão deste caso, enfatizamos os mecanismos patogênicos e o tratamento destas doenças.
Downloads
Referências
Wilson WA, Gharavi AE, Koike T, et al. International consen- sus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international work- shop. Arthritis Rheum 1999;42(7):1309-11.
Rai RS, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 1995;10(12):3301-4.
Rote NS. Antiphospholipid antibodies and recurrent pregnancy loss. Am J Reprod Immunol 1996;35(4):394-401.
Beer AE. Immunologic aspects of normal pregnancy and recur- rent spontaneous abortion. Semin Reprod Endocrinol 1988;6(2):163-78.
Kwak JY, Gilman-Sachs A, Beaman KD, Beer AE. Reproduc- tive outcome in women with recurrent spontaneous abortions of alloimmune and autoimmune causes: preconception versus postconception treatment. Am J Obstet Gynecol 1992;166(6 Pt 1):1787-95; discussion 1795-8.
Peña RB, Cadavid AP, Botero JH, García GP, Gallego MI, Ossa JE. The production of MLR-blocking factors after lymphocyte immunotherapy for RSA does not predict the outcome of preg- nancy. Am J Reprod Immunol 1998;39(2):120-4.
Rand JH. Molecular pathogenesis of the antiphospholipid syn- drome. Circ Res 2002;90(1):29-37.
Sedano M, Palma S, González P, et al. Pérdida recurrente del embarazo en pacientes com anticuerpos anticardiolipinas (AACL) [Recurrent loss of pregnancy in patients with anticardiolipin antibodies (ACAb)]. Rev Chil Obstet Ginecol 1992;57(5):327-32.
Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective stud- ies of the association between anticardiolipin antibody and out- come of pregnancy. Obstet Gynecol 1995;86(4 Pt 1):555-9.
Couto E, Barini R, Pinto e Silva JL, de Moraes DR, de Carvalho LM. Anticardiolipin antibody in recurrent spontaneous abort- ing and fertile women. Rev Paul Med 1998;116(4):1760-5.
Rote NS, Walter A, Lyden TW. Antiphospholipid antibodies-lobsters or red herrings? Am J Reprod Immunol 1992;28(1):31-7.
Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syn- drome: a possible mechanism of thrombosis. Am J Obstet Gynecol 1993;168(1 Pt 1):206-10.
Rand JH, Wu XX, Guller S, Scher J, Andree HA, Lockwood CJ. Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi. Am J Obstet Gynecol 1997;177(4):918-23.
Vogt E, Ng AK, Rote NS. Antiphosphatidylserine antibody re- moves annexin-V and facilitates the binding of prothrombin at the surface of a choriocarcinoma model of trophoblast differentiation. Am J Obstet Gynecol 1997;177(4):964-72.
Vogt E, Ng AK, Rote NS. A model for the antiphospholipid antibody syndrome: monoclonal antiphosphatidylserine anti- body induces intrauterine growth restriction in mice. Am J Obstet Gynecol 1996;174:(2)700-7.
Ober C, Karrison T, Odem RR, et al. Mononuclear-cell immu- nisation in prevention of recurrent miscarriages: a randomised trial. Lancet 1999;354(9176):365-9.
Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996;174(5):1584-9.
Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid anti- bodies (or antiphospholipid antibodies). BMJ 1997; 314(7076):253-7.
Cadavid A, Peña B, García G, et al. Heparin plus aspirin as a “single” therapy for recurrent spontaneous abortion associated with both allo- and autoimmunity. Am J Reprod Immunol 1999;41(4):271-8.
Silver RK, MacGregor SN, Sholl JS, Hobart JM, Neerhof MG, Ragin A. Comparative trial of prednisone plus aspirin versus as- pirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol 1993;169(6):1411-7.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
